|
|||||
|
|
Impact of the National Perinatal Hepatitis B Prevention Programme in the Republic of Korea: A retrospective registry-based cohort study |
|
| Institution: | 1. Division of Vaccine-Preventable Disease Control and National Immunisation Programme, Korea Centres for Disease Control and Prevention, Republic of Korea;2. Complex Disease and Genome Epidemiology Branch, Department of Public Health, Graduate School of Public Health, Seoul National University, Republic of Korea;3. Department of Emergency Medicine, Hallym University, Dongtan Sacred Heart Hospital, Gyounggi, Republic of Korea;4. Global Centre for Infectious Diseases, Seoul National University College of Medicine, Republic of Korea;1. Department of Orthopaedic Surgery, National University Health System, Singapore;2. Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore;3. Department of Emergency Medicine, Singapore General Hospital, Singapore;4. Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore;5. Saw Swee Hock School of Public Health, Yong Loo Lin School of Medicine, National University of Singapore, Singapore;1. Center for Infectious Disease Research, KCDC, Cheongju, South Korea;2. Public Health Agency of Sweden, Solna, Sweden;3. Ministry of Health and Medical Services of Fiji, Suva, Fiji;4. Head-Laboratory Systems and Networks, Zambia National Public Health Institute, Lusaka, Zambia;5. International Cooperation Department, Ministry of Health of Viet Nam, Hanoi, Vietnam;6. Ministry of Health of Chile, Santiago, Chile;7. FDA, Ministry of Public Health, Nonthaburi, Thailand;8. Ministry of Health and Welfare, Sejong, South Korea;1. Division of Pediatric Infectious Diseases, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA;2. Department of Social and Preventive Medicine, Hallym University College of Medicine, Chuncheon, Republic of Korea;3. National Institute of Health, Korea Centers for Disease Control and Prevention, Cheongju, Republic of Korea;4. Expanded Programme on Immunization Unit, World Health Organization Regional Office for the Western Pacific, Manila, Philippines;5. Department of Family Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea;6. Center for Healthy Society and Education, Seoul National University College of Medicine, Seoul, Republic of Korea;1. National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China;2. National Immunization Program, Chinese Center For Disease Control and Prevention, Beijing 100051, China;1. Paediatric Department, Hôpital Antoine Béclère, Hôpitaux Universitaires Paris-Sud, 157 Rue de la Porte de Trivaux, 92140 Clamart, France;2. Université Paris Sud, Le Kremlin Bicêtre, Orsay France;3. Sanofi Pasteur SA, 2 avenue Pont Pasteur, 69367 Lyon Cedex 07, France;4. Sanofi Pasteur MSD, 162 avenue Jean Jaurès, CS 50712, 69367 Lyon Cedex 07, France |
| Abstract: | IntroductionHepatitis B is a major preventable cause of morbidity and mortality from chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. We aimed to evaluate the performance and outcomes of the Korean Perinatal Hepatitis B Prevention Programme (PHBPP) and to investigate the impact of the current post-exposure immunoprophylaxis protocol.MethodsA retrospective cohort study was performed based on electronic data registry of infants born to hepatitis B virus (HBV)-infected mothers between July 2002 and 2013.ResultsDuring the study period, 159,983 Korean infants were registered with the PHBPP, with an overall programme coverage of 92.8%. Despite receiving timely post-exposure immunoprophylaxis, 8.6% of infants born to mothers aged <25 years and hepatitis B e antigen (HBeAg)-positive, and 0.7% of infants born to mothers aged ≥25 years and HBeAg-negative were infected. An estimated 14,123 infants were directly protected from perinatal HBV transmission by the PHBPP during the 11.5-year period, at a cost of 1157 US dollars per case averted. The incidence of paediatric hepatocellular carcinoma declined dramatically during the period.ConclusionsA substantial number of infants have been prevented from hepatitis B since the PHBPP was launched in the Republic of Korea. Continued efforts to promote the programme, an integrated approach to maximising its coverage, a risk-stratified strategy, and innovations in logistics could further reduce perinatal HBV transmission. |
| Keywords: | Hepatitis B vaccine Mother-to-child transmission Hepatitis B Immunisation programme Impact Immunoprophylaxis anti-HBs"} {"#name":"keyword" "$":{"id":"k0040"} "$$":[{"#name":"text" "_":"antibody to HBsAg HepB"} {"#name":"keyword" "$":{"id":"k0050"} "$$":[{"#name":"text" "_":"hepatitis B (disease) HBeAg"} {"#name":"keyword" "$":{"id":"k0060"} "$$":[{"#name":"text" "_":"Hepatitis B e antigen HBIg"} {"#name":"keyword" "$":{"id":"k0070"} "$$":[{"#name":"text" "_":"hepatitis B immune globulin HBsAg"} {"#name":"keyword" "$":{"id":"k0080"} "$$":[{"#name":"text" "_":"hepatitis B surface antigen HBV"} {"#name":"keyword" "$":{"id":"k0090"} "$$":[{"#name":"text" "_":"hepatitis B virus HepB-BD"} {"#name":"keyword" "$":{"id":"k0100"} "$$":[{"#name":"text" "_":"hepatitis B vaccine birth dose OR"} {"#name":"keyword" "$":{"id":"k0111"} "$$":[{"#name":"text" "_":"odds ratio CI"} {"#name":"keyword" "$":{"id":"k0117"} "$$":[{"#name":"text" "_":"confidence interval IHIS"} {"#name":"keyword" "$":{"id":"k0110"} "$$":[{"#name":"text" "_":"Integrated Health Information System IRR"} {"#name":"keyword" "$":{"id":"k0120"} "$$":[{"#name":"text" "_":"incidence rate ratio KCDC"} {"#name":"keyword" "$":{"id":"k9001"} "$$":[{"#name":"text" "_":"Korea Centres for Disease Control and Prevention KNHANES"} {"#name":"keyword" "$":{"id":"k9003"} "$$":[{"#name":"text" "_":"Korea National Health and Nutrition Examination Survey MTCT"} {"#name":"keyword" "$":{"id":"k0130"} "$$":[{"#name":"text" "_":"mother-to-child transmission NHI"} {"#name":"keyword" "$":{"id":"k0140"} "$$":[{"#name":"text" "_":"National Health Insurance NIP"} {"#name":"keyword" "$":{"id":"k0150"} "$$":[{"#name":"text" "_":"national immunisation programme PEI"} {"#name":"keyword" "$":{"id":"k0160"} "$$":[{"#name":"text" "_":"post-exposure immunoprophylaxis PHBPP"} {"#name":"keyword" "$":{"id":"k0170"} "$$":[{"#name":"text" "_":"Perinatal Hepatitis B Prevention Programme PHBPP-IS"} {"#name":"keyword" "$":{"id":"k0180"} "$$":[{"#name":"text" "_":"Perinatal Hepatitis B Prevention Programme Information System PHC"} {"#name":"keyword" "$":{"id":"k0190"} "$$":[{"#name":"text" "_":"public health centre PVST"} {"#name":"keyword" "$":{"id":"k0200"} "$$":[{"#name":"text" "_":"post-vaccination serologic test ROK"} {"#name":"keyword" "$":{"id":"k0210"} "$$":[{"#name":"text" "_":"Republic of Korea WUNEIC"} {"#name":"keyword" "$":{"id":"k0220"} "$$":[{"#name":"text" "_":"World Health Organization-United Nations Children’s Fund National Estimate of Immunization Coverage |
| 本文献已被 ScienceDirect 等数据库收录！ | |